Outcome of Board meeting for Audited Financials results for the year ended 31.03.2023
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vista Pharmaceuticals' board approved its FY23 audited results on May 30, 2023. Revenue from operations rose sharply to Rs 100.37 lakhs from Rs 39.46 lakhs in FY22, but the company reported a much wider net loss of Rs 581.71 lakhs versus Rs 88.85 lakhs the previous year. Total expenses ballooned to Rs 601.14 lakhs (vs Rs 317.78 lakhs), driven by higher raw material costs, depreciation, and finance charges of Rs 121.35 lakhs. The statutory auditor (A.M. Reddy & D.R. Reddy) issued an unmodified/unqualified opinion on the results. The balance sheet remains modestly positive with equity of Rs 3,653.69 lakhs, though operating cash flow stayed negative at Rs -171.55 lakhs, funded partly through share warrant proceeds of Rs 691.93 lakhs.
Deepening losses despite revenue growth signal operational stress and rising costs — likely negative for the stock in the short term. The clean audit opinion offers some comfort, but persistent cash burn and absence of profitability make this a high-risk small-cap pharma name.